Advancing the Treatment Paradigm for mCRPC: Insights into Combination Therapy and Future Directions : Episode 4
Opinion
Video
The Safety Profile of RAD-ENZ
Author(s):
Panelists discuss how the combination of radium-223 and enzalutamide (RAD-ENZ) demonstrated a manageable safety profile in PEACE-3, with bone health monitoring and prophylactic bone-targeted therapy being crucial considerations, particularly given the potential impact on future treatment options.
Video Player is loading.
Video content above is prompted by the following:
- Can you discuss the safety profile of the combination of RAD-ENZ?
- Keeping the safety profile of RAD-ENZ in mind, do you have any concerns about implementing the PEACE 3 protocol and introducing radium treatment as you are thinking about the possible need for future therapies?
Related Videos
NMIBC Treatment Decisions in the Age of BCG Shortages
Current Standards of Care and Shifting Strategies in NMIBC
Targeted Therapy in mHSPC: Effects of Mutation Absence
Real-World Outcomes With Nadofaragene in BCG-Unresponsive NMIBC
An Overview of Nogapendekin Alfa Inbakicept for High-Risk, BCG-Unresponsive NMIBC
Treatment Strategies for Symptomatic Bone Metastases in mHSPC
Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC
Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice
Adoption of New Treatment Modalities to Treat BPH
Safety data on Black patients from ARANOTE
Related Content
